We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Bioequivalence Study of Risperidone Tablet 1 mg Under Fasting Condition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01722201
Recruitment Status : Completed
First Posted : November 6, 2012
Last Update Posted : November 6, 2012
Information provided by (Responsible Party):
IPCA Laboratories Ltd.

Brief Summary:
This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult human subjects.

Condition or disease Intervention/treatment Phase
Fasting Drug: Risperidone Tablet 1 mg Drug: Risperidone Phase 1

Detailed Description:

Objective of this pivotal study was to assess the bioequivalence between Test Product: Risperidone Tablet 1 mg of Ipca Laboratories Limited, India and the corresponding Reference Product: Risperdal® (Risperidone) Tablets 25 mg of Janssen Pharmaceutica Products, USA, under fasting condition in normal, healthy, adult, human subjects in a randomized crossover study.

The study was conducted with 48 healthy adult subjects. In each study period, a single 1 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.

The duration of the clinical phase was approximately 16 days including washout period of at least 10 days between administrations of study drug in each study period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Risperidone Tablet 1 mg With Risperdal® 1 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition
Study Start Date : June 2012
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Risperidone

Arm Intervention/treatment
Experimental: Risperidone Tablet 1 mg
Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
Drug: Risperidone Tablet 1 mg
1 mg tablet once a day
Other Name: Test Product

Active Comparator: Risperdal®
Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
Drug: Risperidone
1 mg tablet once a day
Other Name: Risperdal®

Primary Outcome Measures :
  1. Bioequivalence is based on Cmax and AUC parameters. [ Time Frame: 3 months ]
    Sampling Hours: Pre-dose and at 00.25, 00.50, 00.75, 01.00, 01.25, 01.50, 01.75, 02.00, 02.25, 02.50, 02.75, 03.00, 03.25, 04.00, 05.00, 06.00, 08.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 and 96.00 hours post-dose.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Male and non-female human subjects, age in the range of 18 - 45 years (both inclusive).
  2. Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart.
  3. Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and oral temperature).
  4. Subjects with clinically acceptable findings as determined by haemogram, biochemistry, serology (HIV, Hepatitis B and Hepatitis C), urinalysis, 12 lead ECG and chest X-ray (chest X-ray if required).
  5. Willingness to follow the protocol requirements as evidenced by written informed consent.
  6. Subject willing to give written informed consent.
  7. Confirming and agreeing to, not using any prescription and over the counter medications including vitamins and minerals for 14 days prior to study and during the course of the study.
  8. No history of drug abuse in the past one year.
  9. Non-smokers and non-alcoholics.
  10. For female subject

    • is child bearing potential practicing acceptable method of birth control for the duration of the study as judged by Investigator such as Condom, Foams, Jellies,Diaphragm, Intrauterine device and Abstinence OR
    • is surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the subject).

Exclusion Criteria:

  1. Known history of hypersensitivity to Risperidone, or related drugs.
  2. Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day.
  3. Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
  4. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological or psychiatric diseases and bleeding tendency.
  5. Participation in a clinical drug study or bioequivalence study within 90 days prior to present study.
  6. History of malignancy or other serious diseases.
  7. Refusal to abstain from food for at least ten (10.00) hours prior to receiving the high-fat and high-calorie breakfast and for at least four (04.00) additional hours post-dose in each study period.
  8. Any contraindication to blood sampling or difficulty in accessibility of veins.
  9. Refusal to abstain from fluid for at least 01.00 hour prior to study drug administration and for at least 01.00 additional hour post-dose, in each study period except about 240 mL of water given during administration of study drug.
  10. Refusal to avoid the use of xanthine-containing food or beverages (chocolates,tea, coffee or cola drinks) or fruit juice/grapefruit juice and any alcoholic products for 48.00 hours prior to dosing until the last blood sample collection of last study period.
  11. Blood donation within 90 days prior to the commencement of the study.
  12. Subjects with positive HIV tests or Hepatitis-B or Hepatitis-C tests.
  13. Found positive in breath alcohol test done before check-in for each study period.
  14. Found positive in urine test for drugs of abuse done before check-in for each study period.
  15. Refusal to abstain from consumption of tobacco products 24.00 hours prior to dosing until the last blood sample collection of last study period.
  16. History of problem in swallowing Tablet(s).
  17. Female subject, demonstrating positive urine pregnancy test at the time of screening.
  18. Female subject, demonstrating positive Serum (ß) Beta- hCG (Human Chorionic Gonadotropin) test before check-in for each study period.
  19. Female subject, currently breast feeding or lactating.
  20. Female subjects not willing to use acceptable method of contraception from the date of screening until the completion of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01722201

Layout table for location information
Accutest Research Lab (I) Pvt. Ltd.
Ahmedabad, Gujarat, India
Sponsors and Collaborators
IPCA Laboratories Ltd.
Layout table for investigator information
Principal Investigator: Dr. Tarang Shah, M.D. Accutest Research Lab (I) Pvt. Ltd.
Layout table for additonal information
Responsible Party: IPCA Laboratories Ltd.
ClinicalTrials.gov Identifier: NCT01722201    
Other Study ID Numbers: Ipca/ARL-12/126
First Posted: November 6, 2012    Key Record Dates
Last Update Posted: November 6, 2012
Last Verified: November 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents